A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This is a clinical study to evaluate the safety and pharmacokinetics of an overseas
determined maximum tolerated dose (MTD) of MK-0683 (vorinostat) in a Japanese patient
population with solid tumors.